TUCSON, Ariz., Oct. 12, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, announced the availability of the HTG EdgeSeq Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin Assay (research use only). DLBCL, the most common form of non-Hodgkin's lymphoma (NHL) in adults, is characterized by two major subtypes, activated B-cell-like (ABC) and germinal center B-cell-like (GCB). The HTG EdgeSeq DLBCL Cell of Origin Assay classifies DLBCL as ABC or GCB and was trained and validated on over 250 cases previously subtyped through microarray-based gene expression profiling. Automated on the HTG EdgeSeq system, the assay couples HTG's proprietary nuclease protection chemistry with next-generation sequencing (NGS).
"In many cancers, like DLBCL, it is common for the core needle biopsy to be the only sample available for assessing the nature of the tumor. We believe that the HTG EdgeSeq DLBCL Cell of Origin Assay will be transformational because it enables the subtyping of DLBCL from these minimally invasive samples," stated Chris Roberts, HTG's Senior Vice President of Marketing and Medical Innovation.
In addition, the company also announced the availability of the HTG EdgeSeq Lymphoma Panel which measures the expression of 93 genes frequently assessed in lymphomas, including 22 common NHL markers.
"We are proud to add these two new products to our growing portfolio of NGS-based molecular profiling assays, and we are pleased to enable our customers to perform NGS-based molecular profiling from core needle biopsies" commented TJ Johnson, HTG's Chief Executive Officer. "There is a trend toward a demand for more data from less tissue; we believe that this tissue availability issue will only grow as new biomarker-directed therapies are made available, and our solution will meet that demand," Mr. Johnson added.
About HTG Molecular Diagnostics:
Headquartered in Tucson, Arizona, HTG's mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG's product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with our business and capabilities of our technology. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with trends in market development; market acceptance of our technical solution and/or products; trends in sample requirements; our ability to successfully commercialize our products; and our ability to manufacture our products to meet demand. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the Quarter ended June 30, 2015. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: firstname.lastname@example.org TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: email@example.com
Source:HTG Molecular Diagnostics